Skip to main content
Clinical Trials/NCT00628225
NCT00628225CompletedPhase 4

Smoking Cessation in Patients With COPD (SMOCC) in General Practice

ZonMw: The Netherlands Organisation for Health Research and Development2 sites in 1 country667 target enrollmentStarted: March 1, 2000Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
667
Locations
2
Primary Endpoint
Smoking cessation (point prevalence, both self reported as biochemical verified)

Study Overview

Brief Summary

Background: Smoking cessation is the key element in the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). The role of the general practice in assisting these patients with successful quitting smoking was suboptimal. Therefore we evaluated the effectiveness of two smoking cessation programs (counseling and nicotine replacement) for smokers with COPD in routine general practice, one with (CNB) and one without (CN) the combination with bupropion-SR, compared to usual care (UC) and explored the role of COPD symptoms in successful smoking cessation.

Method: RCT with 667 patients with COPD, 68 general practices were randomly allocated. The usual care group (UC) consisted of 148 patients (22 practices), the first intervention group (counseling plus nicotine replacement (CN) of 243 patients (21 practices) and the second intervention group of 276 patients (25 practices. Main outcome measure was (biochemically verified) point prevalence.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
35 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • A software program using Anatomical Therapeutical Chemical (ATC) prescription codes and International Classification of Primary Care (ICPC) diagnosis codes selected potential patients with COPD. Criteria: age >35 years and a diagnosis recorded as COPD or as ICPC code R95/96, or a prescription of at least three times of bronchodilators (ATC code R03a/bc) and/or prescription of at least two times of inhaled anti-inflammatory medication in the past year (ATC code R03). General practitioners (GPs) had to confirm the diagnosis of the selection. Patients were eligible to participate if they met the following criteria:
  • Current smoking
  • Suffering from COPD according to the GP's diagnosis
  • In command of the Dutch language.

Exclusion Criteria

  • Under control of a chest physician
  • Serious physical or psychological comorbidity

Outcomes

Primary Outcomes

Smoking cessation (point prevalence, both self reported as biochemical verified)

Time Frame: 12 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
ZonMw: The Netherlands Organisation for Health Research and Development
Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials